MARKET

AKBA

AKBA

Akebia
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.630
+0.100
+3.95%
Opening 15:48 07/28 EDT
OPEN
2.540
PREV CLOSE
2.530
HIGH
2.640
LOW
2.510
VOLUME
2.07M
TURNOVER
--
52 WEEK HIGH
12.48
52 WEEK LOW
2.090
MARKET CAP
421.10M
P/E (TTM)
-0.9550
1D
5D
1M
3M
1Y
5Y
Akebia Therapeutics to Report Second Quarter 2021 Financial Results and Discuss Recent Business Highlights
/PRNewswire/ -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the second quarter ended , on before the opening of the fina...
PR Newswire - PRF · 2d ago
NRx Pharma, Cassava Sciences lead weekly healthcare gainers; Seres Therapeutics trail
Artystarty/iStock via Getty Images The healthcare stocks in the S&P 500 finished ~2.2% higher this week to outperform the ~2.0% gain recorded by the broader index over the past five-day period. While
Seekingalpha · 3d ago
American Kidney Fund Supports Emerging Researchers Through Two New Clinical Scientist in Nephrology Fellowship Awards
--News Direct--
News Direct · 07/19 13:00
Thinking about buying stock in Ion Geophysical, Moneygram International, Akebia Therapeutics, iBio, or Exela Technologies?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IO, MGI, AKBA, IBIO, and XELA.
PR Newswire - PRF · 07/16 12:30
GSK reports positive results from Phase 3 daprodustat studies in anaemia due to CKD
designer491/iStock via Getty Images GlaxoSmithKline (GSK) announces positive headline results from five studies of Phase 3 ASCEND program, evaluating the efficacy and safety of daprodustat, for patients with anaemia due
Seekingalpha · 07/16 12:22
AKBA, MRIN and CLPS among pre market gainers
ION Geophysical IO +25% on Q2 preliminary dataAehr Test Systems AEHR +17% announces Q4 2021 ResultsExela  XELA +13%  announces listing of Option Contracts on NYSE ArcaLizhi  LIZI+11%  partnership with Xinghe Zhilian Automotive Technology companyMarin Softw...
Seekingalpha · 07/16 12:20
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers
Benzinga · 07/15 20:34
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
/PRNewswire/ --  (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 25 newly-hired employees options to purchase an aggregate of 210,000 shares of Akebia's common stock on , as ind...
PR Newswire - PRF · 07/01 20:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AKBA. Analyze the recent business situations of Akebia through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AKBA stock price target is 6.57 with a high estimate of 10.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 249
Institutional Holdings: 103.84M
% Owned: 64.85%
Shares Outstanding: 160.12M
TypeInstitutionsShares
Increased
48
13.84M
New
20
2.18M
Decreased
45
15.25M
Sold Out
17
3.62M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.52%
Pharmaceuticals & Medical Research
+1.98%
Key Executives
Non-Executive Chairman/Independent Director
Adrian Adams
President/Chief Executive Officer/Director
John Butler
Chief Financial Officer/Senior Vice President/Treasurer
David Spellman
Chief Operating Officer/Senior Vice President
Michel Dahan
Senior Vice President/Secretary
Nicole Hadas
Senior Vice President
Steven Burke
Senior Vice President
Dell Faulkingham
Independent Director
Steven Gilman
Independent Director
Michael Heffernan
Independent Director
Michael Rogers
Independent Director
Cynthia Smith
Independent Director
Myles Wolf
Independent Director
LeAnne Zumwalt
No Data
  • All
  • Financials
  • Insiders
More
About AKBA
Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in developing vadadustat as an oral therapy. The Company's vadadustat is a HIF-prolyl-hydroxylase (HIF-PH) inhibitor in Phase III development for the treatment of anemia of CKD. In addition to vadadustat, the Company is engaged in developing a HIF-based portfolio of product candidates that target serious diseases of unmet need. Its portfolio includes product candidates developed internally, such as AKB-6899, as well as in-licensed product candidates, including AKB-5169. AKB-5169 is a preclinical compound in development as an oral treatment for inflammatory bowel disease (IBD).

Webull offers kinds of Akebia Therapeutics Inc stock information, including NASDAQ:AKBA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKBA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AKBA stock methods without spending real money on the virtual paper trading platform.